VahatiCor, Inc. is focused on transforming cardiac care for the millions of patients suffering from Coronary Microvascular Dysfunction, a condition that causes angina despite the absence of large-artery blockages. Its core product, the A-FLUX® Reducer System, is a repositionable, self-expanding device that creates a controlled narrowing of the coronary sinus to redistribute oxygenated blood and improve myocardial perfusion. The company is currently running the SERRA-I early feasibility study, which will enroll 30 patients across six clinical sites to evaluate safety and efficacy. Proceeds from the latest financing will also fund continued engineering work and preparations for pivotal trials and regulatory interactions. Investors highlight the device’s potential to become the leading coronary sinus therapy due to its procedural safety and efficacy advantages. Following its $23 million Series B, VahatiCor has the capital needed to progress through key clinical milestones and move closer to market introduction of its breakthrough therapy.

Total raised

$23M

Funding rounds

1

Latest round

Series B

Latest activity

Nov 2025